68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Recruiting · NCT07508852 · Interventional (participants receive a specific treatment) · Lead sponsor: Peking University First Hospital
View the official record on ClinicalTrials.gov →Interventions studied
Sequential [18F]-FDG PET/CT[68Ga]Ga-PFD3 PET/CT scan
What this trial is about
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adults.
- Histologically confirmed small cell lung cancer (SCLC).
- At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
- Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.
Exclusion criteria
- Pregnancy.
- Breastfeeding.
- Acute psychiatric disorders.
- Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
- Inability to complete the study procedures as anticipated.
- Prior therapy targeting DLL3.
Where it is running
1 location listed.
- Peking university first hospital nuclear medicine - Beijing, Beijing Municipality, China